EcN-Sj16-Exo通过上调N-WASP抑制嗜酸性粒细胞胞外诱捕网形成改善实验性哮喘
本研究提取表达日本血吸虫Sj16蛋白的大肠杆菌Nissle 1917分泌的外泌体(EcN-Sj16-Exo),在卵清蛋白诱导的小鼠哮喘模型中探究其作用。结果显示EcN-Sj16-Exo可减少EET形成,减轻气道高反应性、气道重塑和炎症,机制为上调N-WASP。
要点
- 哮喘患者痰和BALF中EET形成增加。
- EcN-Sj16-Exo减少小鼠哮喘模型EET形成并改善气道炎症和重塑。
- EcN-Sj16-Exo通过上调N-WASP抑制EET形成。
核心结论
- EcN-Sj16-Exo是哮喘的潜在治疗手段,靶向EET和N-WASP具有治疗潜力。
研究设计与样本
- 研究提取工程化表达Sj16的EcN分泌的外泌体(EcN-Sj16-Exo),在卵清蛋白诱导的小鼠实验性哮喘模型中治疗,并用WASL敲除小鼠和rAAV表达N-WASP探讨机制。
主要发现
- 哮喘患者痰和BALF中EET形成增加。
- Sj16在体外抑制EET形成,当由EcN-Sj16分泌时主要定位于外泌体。
- 在实验性哮喘模型中,EcN-Sj16-Exo显著减少EET形成。
- EcN-Sj16-Exo显著减轻气道高反应性和气道重塑,表现为肺阻力降低、动态顺应性改善及炎症细胞浸润、纤维化和黏液高分泌减少。
- EcN-Sj16-Exo降低BALF中嗜酸性粒细胞和中性粒细胞计数、IgE水平和2型细胞因子水平,同时增加脾脏T调节细胞。
临床怎么用
- EcN-Sj16-Exo可能作为哮喘治疗策略,通过上调N-WASP抑制EET形成。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Eosinophilic inflammation is a feature of allergic asthma, with eosinophil depletion shown to alleviate symptoms. Elevated levels of eosinophil extracellular traps (EETs) in bronchoalveolar lavage fluid (BALF) correlate with asthma severity. Sj16 is a protein from Schistosoma japonicum with known immunoregulatory properties. Exosomes, with their protective phospholipid bilayer, serve as efficient drug carriers. METHODS: We extracted exosomes secreted by Escherichia coli Nissle 1917 engineered to express Sj16 (EcN-Sj16-Exo), and sought to investigate the role of EcN-Sj16-Exo in asthma. In an ovalbumin-induced experimental asthma model in mice, EET levels were elevated. The experimental asthma model was treated with EcN-Sj16-Exo. EET formation was assessed using immunofluorescence and scanning electron microscopy. Lung function, airway remodelling and inflammation were evaluated. Wiskott-Aldrich syndrome-like (WASL) knockout mice and recombinant adeno-associated virus (rAAV)-expressing neural Wiskott-Aldrich syndrome protein (N-WASP) were used to investigate the potential mechanisms of EcN-Sj16-Exo. RESULTS: EET formation is increased in sputum and BALF from patients with asthma. We demonstrate that Sj16 inhibits EET formation in vitro and localises primarily in exosomes when secreted by EcN-Sj16. In the experimental asthma model, EcN-Sj16-Exo significantly reduced EET formation. Moreover, EcN-Sj16-Exo significantly attenuated airway hyperreactivity and airway remodelling, as evidenced by reduced lung resistance, improved dynamic compliance and diminished inflammatory cell infiltration, fibrosis and mucus hypersecretion. Furthermore, EcN-Sj16-Exo decreased eosinophil and neutrophil counts, IgE levels and type 2 cytokine levels in BALF while increasing T-regulatory cells in the spleen. Mechanistically, EcN-Sj16-Exo inhibited EET formation by upregulating N-WASP. WASL-knockout mice and AAV6-WASL-mediated N-WASP expression confirmed that EcN-Sj16-Exo alleviates experimental asthma by upregulating N-WASP to inhibit EET formation. CONCLUSION: Our findings suggest that EcN-Sj16-Exo represents a promising therapeutic approach in asthma, highlighting the potential of targeting EETs and N-WASP in asthma therapy.
引用
- Sun X, Liao Y, Wu J, et al. EcN-Sj16-Exo ameliorates experimental asthma by inhibiting eosinophil extracellular trap formation via N-WASP upregulation. Eur Respir J. 2026. PMID: 41713945. doi:10.1183/13993003.00948-2025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。